Swiss medical technology giant Ypsomed recently announced a long-term autoinjector supply agreement with Novo Nordisk.This collaboration not only demonstrates the leading position of Danish pharmaceutical companies in the weight-loss drug field but also brings new opportunities to the entire pharmaceutical services industry.

The market reacted enthusiastically to this collaboration, with Ypsomed's stock price quickly rising by 5% after the announcement.Ypsomed will provide these autoinjectors for Novo Nordisk's "second-generation GLP-1s." These drugs are currently in clinical trials and are expected to officially enter the market in the coming years.

Ypsomed CEO Simon Michel said: "The signing of this contract marks an important milestone for Ypsomed. The long-term cooperation significantly and continuously supports our growth strategy. We are pleased to be able to provide simple and safe treatment at home with our devices for people suffering from chronic diseases."

Ypsomed also develops insulin pumps for diabetes patients. Its YpsoPump, as an automated insulin delivery system compatible with certain software and glucose monitors, represents a leading product.

Abbott and WeightWatchers Announce Blood Glucose Monitoring Connection App on September 19The program was announced in August 2022 as a collaboration aimed at combining continuous glucose monitoring (CGM) with a globally tailored diabetes program. The integrated product provides people with diabetes the necessary information and insights, offering a mobile experience. It helps them make healthy adjustments to their diet, improve their glucose levels, and gain better control over their health.

On September 15, Dexcom announced the launch of its Dexcom One real-time continuous glucose monitoring (CGM) system in France.Real-time CGM sensors are now covered by health insurance in France, bringing this technology to 500,000 diabetes patients in France who were not using CGM. The company ensures that all type 1 and type 2 diabetes patients aged 2 years and above undergoing intensive insulin therapy can access the platform.

Dexcom One continuously monitors glucose levels in real time, wirelessly sending the values to compatible smart devices via an app or receiver, and then displaying trend arrows to indicate the speed and direction of glucose levels. It also features a range of customizable alerts and access to Clarity data management software for remote data sharing with HCPs. It uses the G6 hardware platform with a different software experience.

The development prospects of medical devices for diabetes treatment are very optimistic. With technological innovation and the growth of medical needs, this field is expected to achieve higher precision in diagnosis and more effective treatment methods. This is a field worth attention and investment, with huge market potential and social value.

Ypsomed is a leading developer and manufacturer in the field of self-medication injection and infusion systems and a diabetes specialist with over 35 years of experience. As a pioneer in innovation and technology, the company has become a preferred partner for pharmaceutical and biotech enterprises, offering a variety of pen injectors, auto-injectors, and pump systems for liquid drug administration. Through the mylife brand, Ypsomed provides its product portfolio directly or via pharmacies and hospitals to people with diabetes, while also engaging in business-to-business collaborations with pharmaceutical companies under the framework of YDS (Ypsomed Delivery Systems).

Novo Nordisk (Novo Nordisk A/S) was founded in 1989 through the merger of two Danish companies, Nordisk Gentofte A/S and Novo Industri A/S. As a global healthcare giant, the company holds a leading position worldwide in diabetes treatment. Its product portfolio includes not only novel insulins but also a comprehensive range of modern products, as well as a once-daily GLP-1 analog. In addition,Novo NordiskAlso holds a leading position in hemophilia care, growth hormone therapy, and hormone replacement therapy.

This collaboration not only deepened the relationship between Ypsomed andNovo NordiskThe partnership in the fields of medical technology and pharmaceuticals has brought more treatment options to diabetic and obese patients worldwide. The collaboration between the two companies heralds infinite possibilities for the future in this field.